By: Jacklyn Wille- Bloomberg
![](http://bluesantitrustlitigation.com/wp-content/uploads/2022/06/bloomberg.png)
Blue Cross Blue Shield of North Carolina was hit with a proposed class action by two prostate cancer patients who say the company wrongly refuses to cover a well-established cancer treatment by incorrectly classifying it as experimental.